Satellos Bioscience Inc. announced it will host a virtual KOL (Key Opinion Leader) event on SAT-3247 for Duchenne Muscular Dystrophy, with the event dated February 18, 2026. This event is significant for investors as it highlights ongoing developments in the company's therapeutic efforts.